Diagnostic Pathology of Lung Cancer

Abstract

In the past 5 years, there has arguably been a shift in the pathologic diagnosis of lung cancer, especially adenocarcinoma, moving toward a more patient-centered approach to reporting that works to incorporate information that may be clinically meaningful to prognosis and impactful to clinical management strategy. As the demand for specialty team care surges, the need for effective communication between specialties continues to increase, particularly to ensure that we are all speaking the same language with regard to diagnostic certainty and the implementation of new terminology. This review of lung cancer pathology is not all-inclusive; but rather, in addition to providing salient histologic and immunohistochemical features of selected topics in adenocarcinoma, squamous cell carcinoma, neuroendocrine tumors, and large cell carcinoma, it also attempts to highlight problems in cancer diagnosis from the pathologist's perspective, including addressing variations in interobserver agreement and limitations to the diagnostic process with regard to immunohistochemistry. In the end, many times, problematic cases might reach resolution not through the narrow-sighted ocular of pathology, but rather through employment of a multidisciplinary approach.

Keywords

pathology - histology - lung cancer - review

• References

• 1 Committee on Diagnostic Error in Health Care. Improving Diagnosis in Health Care. Washington (DC): National Academies Press (US); 2015 December 1–18
• 2 Travis WD, Brambilla E, Noguchi M , et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6 (2) 244-285
• 3 Travis WD, Noguchi M, Yatabe Y , et al. Adenocarcinoma. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, , eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon: International Agency for Research on Cancer; 2015: 26-50
• 4 Qi LP, Li XT, Yang Y , et al. Multivariate analysis of pleural invasion of peripheral non-small cell lung cancer-based computed tomography features. J Comput Assist Tomogr 2016;
• 5 Noguchi M, Morikawa A, Kawasaki M , et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75 (12) 2844-2852
• 6 Liu QX, Deng XF, Zhou D, Li JM, Min JX, Dai JG. Visceral pleural invasion impacts the prognosis of non-small cell lung cancer: a meta-analysis. Eur J Surg Oncol 2016; ;pii: S0748-7983(16)00394-2
• 7 Shiono S, Yanagawa N. Spread through air spaces is a predictive factor of recurrence and a prognostic factor in stage I lung adenocarcinoma. Interact Cardiovasc Thorac Surg 2016; ;pii:ivw211
• 8 Yoshizawa A, Motoi N, Riely GJ , et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011; 24 (5) 653-664
• 9 Thunnissen E, Noguchi M, Aisner S , et al. Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. J Thorac Oncol 2014; 9 (9) 1354-1362
• 10 Moon Y, Kim KS, Sung SW , et al. Correlation of histological components with tumor invasion in pulmonary adenocarcinoma. World J Surg Oncol 2014; 12: 388
• 11 Hung JJ, Yeh YC, Jeng WJ, Wu YC, Chou TY, Hsu WH. Factors predicting occult lymph node metastasis in completely resected lung adenocarcinoma of 3 cm or smaller. Eur J Cardiothorac Surg 2016; 50 (2) 329-336
• 12 Zhao Y, Wang R, Shen X , et al. Minor components of micropapillary and solid subtypes in lung adenocarcinoma are predictors of lymph node metastasis and poor prognosis. Ann Surg Oncol 2016; 23 (6) 2099-2105
• 13 Sakurai H, Maeshima A, Watanabe S , et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol 2004; 28 (2) 198-206
• 14 Boland JM, Froemming AT, Wampfler JA , et al. Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma-analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules. Hum Pathol 2016; 51: 41-50
• 15 Noguchi M, Minami Y, Iijima T, Matsuno Y. Reproducibility of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteria. Pathol Int 2005; 55 (1) 8-13
• 16 Thunnissen E, Beasley MB, Borczuk AC , et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 2012; 25 (12) 1574-1583
• 17 Sakurai H, Dobashi Y, Mizutani E , et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg 2004; 78 (5) 1728-1733
• 18 Kadota K, Villena-Vargas J, Yoshizawa A , et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol 2014; 38 (4) 448-460
• 19 Maeshima AM, Tochigi N, Yoshida A, Asamura H, Tsuta K, Tsuda H. Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator. J Thorac Oncol 2010; 5 (3) 333-339
• 20 El-Maqsoud NM, Tawfiek ER, Abdelmeged A, Rahman MF, Moustafa AA. The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas. Tumour Biol 2016; 37 (3) 3123-3134
• 21 Kadota K, Nitadori J, Sarkaria IS , et al. Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma. Cancer 2013; 119 (5) 931-938
• 22 Wu J, Chu PG, Jiang Z, Lau SK. Napsin A expression in primary mucin-producing adenocarcinomas of the lung: an immunohistochemical study. Am J Clin Pathol 2013; 139 (2) 160-166
• 23 Haninger DM, Kloecker GH, Bousamra Ii M, Nowacki MR, Slone SP. Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature. Mod Pathol 2014; 27 (4) 535-542
• 24 Lin LI, Xu CW, Zhang BO , et al. Clinicopathological observation of primary lung enteric adenocarcinoma and its response to chemotherapy: a case report and review of the literature. Exp Ther Med 2016; 11 (1) 201-207
• 25 Lindeman NI, Cagle PT, Beasley MB , et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013; 137 (6) 828-860
• 26 Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L , et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist 2015; 20 (3) 316-322
• 27 Heymann JJ, Bulman WA, Maxfield RA , et al. Molecular testing guidelines for lung adenocarcinoma: utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples. Cytojournal 2014; 11: 12
• 28 Wang S, Yu B, Ng CC , et al. The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. Transl Lung Cancer Res 2015; 4 (2) 119-125
• 29 Minca EC, Lanigan CP, Reynolds JP , et al. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material. J Thorac Oncol 2014; 9 (4) 464-468
• 30 Roh MH. The utilization of cytologic fine-needle aspirates of lung cancer for molecular diagnostic testing. J Pathol Transl Med 2015; 49 (4) 300-309
• 31 Wu HH, Eaton JP, Jones KJ , et al. Utilization of cell-transferred cytologic smears in detection of EGFR and KRAS mutation on adenocarcinoma of lung. Mod Pathol 2014; 27 (7) 930-935
• 32 Hironaka M, Fukayama M. Pulmonary fibrosis and lung carcinoma: a comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. Pathol Int 1999; 49 (12) 1060-1066
• 33 Tatsumori T, Tsuta K, Masai K , et al. p40 is the best marker for diagnosing pulmonary squamous cell carcinoma: comparison with p63, cytokeratin 5/6, desmocollin-3, and sox2. Appl Immunohistochem Mol Morphol 2014; 22 (5) 377-382
• 34 Chang SY, Keeney M, Law M, Donovan J, Aubry MC, Garcia J. Detection of human papillomavirus in non-small cell carcinoma of the lung. Hum Pathol 2015; 46 (11) 1592-1597
• 35 Swarts DR, Ramaekers FC, Speel EJ. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta 2012; 1826 (2) 255-271
• 36 Swarts DR, van Suylen RJ, den Bakker MA , et al. Interobserver variability for the WHO classification of pulmonary carcinoids. Am J Surg Pathol 2014; 38 (10) 1429-1436
• 37 Beasley MB, Thunnissen FB, Brambilla E , et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000; 31 (10) 1255-1265
• 38 Lee KW, Lee Y, Oh SW, Jin KN, Goo JM. Large cell neuroendocrine carcinoma of the lung: CT and FDG PET findings. Eur J Radiol 2015; 84 (11) 2332-2338
• 39 Mlika M, Zendah I, Braham E, El Mezni F. CD56 antibody: old-fashioned or still trendy in endocrine lung tumors. J Immunoassay Immunochem 2015; 36 (4) 414-419
• 40 Nicholson SA, Beasley MB, Brambilla E , et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002; 26 (9) 1184-1197
• 41 Quinn AM, Blackhall F, Wilson G , et al. Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics. Histopathology 2012; 61 (3) 454-464
• 42 Hiroshima K, Iyoda A, Shida T , et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol 2006; 19 (10) 1358-1368
• 43 Zhang C, Schmidt LA, Hatanaka K, Thomas D, Lagstein A, Myers JL. Evaluation of napsin A, TTF-1, p63, p40, and CK5/6 immunohistochemical stains in pulmonary neuroendocrine tumors. Am J Clin Pathol 2014; 142 (3) 320-324